Unsal Aykut A, Kılıç Suat, Dubal Pariket M, Baredes Soly, Eloy Jean Anderson
Department of Otolaryngology & Facial Plastic Surgery, Rowan University School of Osteopathic Medicine, Stratford, New Jersey, USA.
Department of Otolaryngology - Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
Auris Nasus Larynx. 2018 Aug;45(4):815-824. doi: 10.1016/j.anl.2017.09.009. Epub 2017 Oct 19.
Sinonasal cancers (SNC) are rare, thus limiting previous prognostic studies on a multinational level. The aim of this study is to utilize two population-based datasets to compare prognoses for SNC between the United States (US) and Europe.
The European Cancer Registry (EUROCARE) database and the United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database were searched to identify survival of patients diagnosed with SNC between 1990 and 2007. Relative survival (RS) data were stratified by age group, gender, geographic location, and diagnostic time period.
12,541 SNC cases were identified in EUROCARE, while SEER identified 4,312. Males comprised the majority in Europe (62.3%) and the US (58.3%). Most patients were over 55 years in Europe (77.0%) and the US (69.5%). Age over 75 was a statistically significant poor prognostic indicator for 5-year RS in the US (48.2%; 95% CI=[43.9, 52.4]) and Europe (38.5%; [34.7, 42.7]). Female gender imparted a favorable 5-year RS in all regions except in Central Europe. By region, the US had the highest 5-year RS (58.8%; [56.4, 61.1]) and Eastern Europe had the lowest 5-year RS (37.1%; [34.0, 40.6]). The aggregate European 5-year RS was 48.1% [46.4, 49.8].
SNC in Europe and the US most commonly affects males and individuals over the age of 55 years. Male gender and age over 75 are poor prognostic factors at 5 years. Five-year RS in the US is higher than the 5-year European aggregate RS.
鼻窦癌（SNC）较为罕见，因此限制了此前在多国层面上的预后研究。本研究的目的是利用两个基于人群的数据集，比较美国和欧洲SNC的预后情况。
检索欧洲癌症登记处（EUROCARE）数据库和美国国立癌症研究所的监测、流行病学和最终结果（SEER）数据库，以确定1990年至2007年期间被诊断为SNC的患者的生存率。相对生存（RS）数据按年龄组、性别、地理位置和诊断时间段进行分层。
EUROCARE数据库中识别出12541例SNC病例，而SEER数据库中识别出4312例。在欧洲，男性占大多数（62.3%），在美国男性占比为58.3%。欧洲大多数患者年龄超过55岁（77.0%），美国为69.5%。在美国（48.2%；95%可信区间=[43.9, 52.4]）和欧洲（38.5%；[34.7, 42.7]），75岁以上年龄是5年RS的统计学显著不良预后指标。除中欧外，女性在所有地区的5年RS均较好。按地区划分，美国的5年RS最高（58.8%；[56.4, 61.1]），东欧的5年RS最低（37.1%；[34.0, 40.6]）。欧洲的总体5年RS为48.1%[46.4, 49.8]。
欧洲和美国的SNC最常见于男性和55岁以上的个体。男性性别和75岁以上年龄是5年时的不良预后因素。美国的5年RS高于欧洲的总体5年RS。
